Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →This acquisition builds on our strategic commitment to invest in our Health Information Systems business and expands the capabilities of our revenue cycle…
M*Modal generates roughly $200 million in annual revenue and brings ~750 employees. Notable history: filed Chapter 11 in 2014 after 2012 acquisition by One…
3M completed the $1B acquisition of M*Modal's technology business, framed as a strategic expansion of revenue cycle management and population health. Excluded:…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
3M agreed to acquire M*Modal's technology business for $1.0 billion in enterprise value to strengthen 3M Health Information Systems with AI-powered clinical documentation. Closed in Q2 2019.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| 3M Company / M*Modal (this deal) | 2019 | $1.0B | — |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
| Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. | 2016 | $17.6B | 91 |
| DPx Holdings B.V. (JLL Partners 51% / Royal DSM 49%) / Patheon Inc. + DSM Pharmaceutical Products | 2013 | $2.6B | 90 |
| Pamplona Capital Management, LLP / PAREXEL International Corporation | 2017 | $5.0B | 90 |
← Browse all deals · How we score deals
More: 2019 deals · Other deals